Cargando…
EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutatio...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518197/ https://www.ncbi.nlm.nih.gov/pubmed/30999636 http://dx.doi.org/10.3390/jcm8040529 |
_version_ | 1783418411206836224 |
---|---|
author | Chalela, Roberto Bellosillo, Beatriz Curull, Víctor Longarón, Raquel Pascual-Guardia, Sergi Badenes-Bonet, Diana Arriola, Edurne Sánchez-Font, Albert Pijuan, Lara Gea, Joaquim |
author_facet | Chalela, Roberto Bellosillo, Beatriz Curull, Víctor Longarón, Raquel Pascual-Guardia, Sergi Badenes-Bonet, Diana Arriola, Edurne Sánchez-Font, Albert Pijuan, Lara Gea, Joaquim |
author_sort | Chalela, Roberto |
collection | PubMed |
description | Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutations observed in ADC can also be observed in the non-neoplastic lung tissue, as well as the short-term prognosis implications of this finding. Methods: Non-tumoral lung parenchyma specimens obtained during surgery from 47 patients with EGFR and/or KRAS abnormalities in their ADC tumors underwent similar genomic testing. Short-term outcomes were also recorded. Results: The same mutations were present in the tumor and the histologically normal tissue in 21.3% of patients (SM group). Although local recurrences were similar in both groups, distant metastases were more frequent in the former (60 vs. 5.4%, p < 0.001). Moreover, SM patients showed lower time-to-progression (8.5 vs. 11.7 months, p < 0.001) and disease-free survival (8.5 vs. 11.2 months, p < 0.001). COX regression showed a higher risk of progression or death (DFS) in the SM group (HR 5.94, p < 0.01]. Similar results were observed when adjusting for potential confounding variables. Conclusions: These results confirm that genetic changes are present in the apparently normal lung in many ADC patients, and this finding has prognostic implications. |
format | Online Article Text |
id | pubmed-6518197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65181972019-05-31 EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma Chalela, Roberto Bellosillo, Beatriz Curull, Víctor Longarón, Raquel Pascual-Guardia, Sergi Badenes-Bonet, Diana Arriola, Edurne Sánchez-Font, Albert Pijuan, Lara Gea, Joaquim J Clin Med Article Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutations observed in ADC can also be observed in the non-neoplastic lung tissue, as well as the short-term prognosis implications of this finding. Methods: Non-tumoral lung parenchyma specimens obtained during surgery from 47 patients with EGFR and/or KRAS abnormalities in their ADC tumors underwent similar genomic testing. Short-term outcomes were also recorded. Results: The same mutations were present in the tumor and the histologically normal tissue in 21.3% of patients (SM group). Although local recurrences were similar in both groups, distant metastases were more frequent in the former (60 vs. 5.4%, p < 0.001). Moreover, SM patients showed lower time-to-progression (8.5 vs. 11.7 months, p < 0.001) and disease-free survival (8.5 vs. 11.2 months, p < 0.001). COX regression showed a higher risk of progression or death (DFS) in the SM group (HR 5.94, p < 0.01]. Similar results were observed when adjusting for potential confounding variables. Conclusions: These results confirm that genetic changes are present in the apparently normal lung in many ADC patients, and this finding has prognostic implications. MDPI 2019-04-17 /pmc/articles/PMC6518197/ /pubmed/30999636 http://dx.doi.org/10.3390/jcm8040529 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chalela, Roberto Bellosillo, Beatriz Curull, Víctor Longarón, Raquel Pascual-Guardia, Sergi Badenes-Bonet, Diana Arriola, Edurne Sánchez-Font, Albert Pijuan, Lara Gea, Joaquim EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma |
title | EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma |
title_full | EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma |
title_fullStr | EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma |
title_full_unstemmed | EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma |
title_short | EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma |
title_sort | egfr and kras mutations in the non-tumoral lung. prognosis in patients with adenocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518197/ https://www.ncbi.nlm.nih.gov/pubmed/30999636 http://dx.doi.org/10.3390/jcm8040529 |
work_keys_str_mv | AT chalelaroberto egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma AT bellosillobeatriz egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma AT curullvictor egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma AT longaronraquel egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma AT pascualguardiasergi egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma AT badenesbonetdiana egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma AT arriolaedurne egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma AT sanchezfontalbert egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma AT pijuanlara egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma AT geajoaquim egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma |